Under this reorganization, the company is combining its discovery chemistry and biology functions into a single unit across locations worldwide. Customers will better benefit from AMRI’s experience in performing fully coordinated multidisciplinary discovery projects utilizing a global network of scientific experts, laboratories and equipment in medicinal chemistry, biology and/or ADMET.
“AMRI has been involved in numerous integrated discovery projects for a number of years,” said Dr. Sargent. “Our experience in successfully developing projects both internally and in collaboration with customers stands as a testament to our ability to provide a high level of project management, well developed and tested solutions, and added-value to our customers.”
“Customers are increasingly seeking out CROs that can provide them with fully integrated solutions in their pursuit to diminish costs and project timelines, while still desiring to maintain a high level of quality and value,” said Chairman, CEO and President Thomas E. D’Ambra, Ph.D. “We believe that combining all of our discovery capabilities in biology and discovery chemistry under the direction of Dr. Sargent will further enhance AMRI’s ability to generate significant value for our customers and stakeholders.”
About AMRI
Founded in 1991, Albany Molecular Research, Inc. provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world’s leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.
Forward-Looking Statement
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, without limitation, statements regarding the company's clinical development plans for its proprietary compounds and the company’s research programs. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to delay or denial of approvals from the FDA, potential changes in the cost, scope and duration of clinical trials as compared to the company’s current expectations, the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission on March 12, 2010 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6563366<=en
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6563366 Contact:
Albany Molecular Research, Inc. Media Andrea Schulz, 518-512-2226 Director of Corporate Communications or Investors Peter Jerome, 518-512-2220 Director of Investor Relations
